0000899243-22-030735.txt : 20220909 0000899243-22-030735.hdr.sgml : 20220909 20220909164625 ACCESSION NUMBER: 0000899243-22-030735 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220908 FILED AS OF DATE: 20220909 DATE AS OF CHANGE: 20220909 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Henn Matthew R. CENTRAL INDEX KEY: 0001767321 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 221236640 MAIL ADDRESS: STREET 1: C/O SERES THERAPEUTICS, INC. STREET 2: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-09-08 0 0001609809 Seres Therapeutics, Inc. MCRB 0001767321 Henn Matthew R. C/O SERES THERAPEUTICS, INC. 200 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 See Remarks Stock Option (Right to Buy) 10.84 2022-09-08 4 A 0 35000 0.00 A 2022-09-08 2027-07-18 Common Stock 35000 35000 D On June 19, 2017, the Reporting Person was granted an option to purchase 70,000 shares of the Issuer's common stock. Subject to the Reporting Person's continued service to the Issuer through each applicable vesting date, the option vests and becomes exercisable in two equal installments upon the satisfaction of certain performance criteria. On September 8, 2022, the Issuer's Board of Directors determined that the performance criteria for the first installment were met, resulting in vesting of the option as to 35,000 shares. Chief Scientific Officer and EVP /s/ Thomas J. DesRosier, attorney-in-fact for Matthew R. Henn 2022-09-09